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Abstract 
The proportion of asymptomatic carriers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains 
elusive and the potential benefit of systematic screening during the SARS-CoV-2-pandemic is controversial. We 
investigated the proportion of asymptomatic inpatients who were identified by systematic screening for SARS-CoV-2 
upon hospital admission. Our analysis revealed that systematic screening of asymptomatic inpatients detects a low 
total number of SARS-CoV-2 infections (0.1%), questioning the cost–benefit ratio of this intervention. Even when the 
population-wide prevalence was low, the proportion of asymptomatic carriers remained stable, supporting the need 
for universal infection prevention and control strategies to avoid onward transmission by undetected SARS-CoV-2-car-
riers during the pandemic.
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Background
Infections with the novel severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) display a wide range 
of symptoms ranging from fatal sepsis with pulmonary 
failure, classical symptoms of a viral respiratory tract 
infection, atypical symptoms, such as anosmia and ageu-
sia and the lack of any detectable disease manifestation 
[1]. The proportion of asymptomatic SARS-CoV-2 infec-
tions remains elusive, with studies suggesting a range of 
2–100% [2–5] depending on the studied population and 
the epidemiological setting. Asymptomatic carriers of 
SARS-CoV-2 may drive ongoing transmission of SARS-
CoV-2, thus maintaining the pandemic [6, 7]. Although 
the secondary attack rate of asymptomatic carriers seems 
to be lower than that of symptomatic patients [3, 8], a rel-
evant proportion of seemingly healthy but SARS-CoV-2 
transmitting people may limit the impact of contact 
tracing and omission of subsequent spread significantly. 
Resources in terms of workforce, testing materials and 
personal protective equipment may be particularly 
restricted in the setting of a pandemic, so that they 
should be allocated to the most effective points of appli-
cation. As the diagnostic yield of systematic screening to 
detect asymptomatic SARS-CoV-2-carriers on admission 
to an acute care facility is controversial, we investigated 
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Methods
All adult patients admitted from 01.04.2020 to 14.06.2020 
to the University Hospital Basel, a tertiary care center 
in Switzerland with more than 35,000 hospital admis-
sions annually, were routinely tested for SARS-CoV-2 
within 72  h of admission. Nasopharyngeal swabs were 
performed by a specially trained and dedicated team 
throughout the study period. An internally developed 
reverse transcription quantitative nucleic acid assay [9] 
and a commercial assay (E-gene; Roche, Rotkreuz, Swit-
zerland) were used to detect SARS-CoV-2 RNA. Each 
patient screened during the study period was retrospec-
tively classified as symptomatic or asymptomatic for 
coronavirus disease 2019 (COVID-19) at time of testing 
based on medical chart review. The classification criteria 
were the same as for the clinical consideration of COVID-
19 and consistently applied during the screening period: 
acute pulmonary symptoms and/or fever ≥ 38.0  °C and/
or sudden onset of anosmia or ageusia, and/or acute 
confusion or deterioration in the elderly, unless other-
wise explained. The number of positive tested patients in 
the Canton Basel-Stadt, the main catchment area of the 
University Hospital Basel, was surveyed by and retrieved 
from the cantonal authorities [10] with most SARS-
CoV-2 tests deriving from the triage- and test center of 
the University Hospital Basel [11]. Categorical variables 
were summarized as counts and proportions and contin-
uous variables as medians and interquartile ranges. The 
Fisher’s exact test was used to assess differences between 
proportions. Approval by the local ethics committee was 
obtained (EKNZ-Number Req-2020-00808). We adhered 
to the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines [12].
Results
During the study period, 4466 screening samples were 
collected from 4099 consecutive admitted patients. 49.9% 
of patients were female, the median age was 63  years 
(interquartile range 45–77  years). 2296 (51.4%), 1591 
(35.6%), and 579 (13.0%) screenings were performed 
in the medical, surgical, and gynecology and obstetrics 
wards, respectively. Forty-two samples were excluded 
from further analyses, as they were collected for further 
follow-up (40 samples) or to screen contact patients (2 
samples). 4050 (90.7%) screenings were classified as col-
lected from asymptomatic patients at the time of test-
ing. A total of 26 screenings (0.6%) tested positive for 
SARS-CoV-2: six of which were taken from asymp-
tomatic patients (23.1% of all positive and 0.1% of all 
asymptomatic patients respectively) (Fig.  1). One out of 
six asymptomatic SARS-CoV-2-positive patients became 
symptomatic over the course of the hospitalization. 














6 SARS-CoV-2 positive samples
0.1% of all asymptomatic screening samples




20 SARS-CoV-2 positive samples
5.3% of all symptomatic screening samples




Fig. 1 Results of SARS-CoV-2 screening samples from asymptomatic and symptomatic patients (overall and stratified by ward types)
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However, symptoms could also be explained by the con-
comitant diagnosis of pyelonephritis. During the study 
period, the Canton Basel-Stadt reported 676 SARS-CoV-
2-infections 44with an average population of 201′504 
people (prevalence 0.3%) [10, 13]. The proportion of 
asymptomatic patients among all SARS-CoV-2-infected 
inpatients remained constant throughout the study 
period (21% (4/19) in April, 33% (2/6) in May, 0% (0/0) 
in June, p = 0.634), while the population-wide prevalence 
decreased.
Discussion
Systematic screening of asymptomatic inpatients 
revealed a low total number of SARS-CoV-2 infections, 
yet a stable proportion of asymptomatic carriers over 
time.
This result is in line with other findings. Lavezzo et al. 
investigated the effects of lockdown and social distanc-
ing in the Italian town of Vo. They routinely tested over 
70% of the community with nasopharyngeal swabs at the 
beginning of the lockdown in February 2020 and again, 
2  weeks later, in March 2020. The prevalence of SARS-
CoV-2 decreased from 2.6 to 1.2%. Symptoms in posi-
tive tested participants were systematically recorded. 
Notably, approximately 40% of people who tested posi-
tive were asymptomatic at both survey time-points [14]. 
The overall proportion of 23.1% of positive screenings in 
asymptomatic patients, identified in our study, was in the 
middle to lower range of reported asymptomatic infec-
tions in other studies: under 50% after direct contact with 
patients [3, 15] and in nursing home staff [16, 17], up 
to 75% in general population testing [14], up to 100% in 
health care workers [4], and 45% [18]–100% [5] in obstet-
ric patients. In our sample, median age was 63  years. 
Higher age may correlate with the development of typi-
cal clinical symptoms of COVID-19 [19]. A recent meta-
analysis found that in obstetric patients, 95% (45–100%) 
of SARS-CoV-2 infections were asymptomatic, whereas 
asymptomatic SARS-CoV-2 infection among nursing 
home residents occurred in 54% (42–65%) of patients 
[20] supporting a higher proportion of asymptomatic 
courses among younger age groups. High proportions 
of asymptomatic infections in both young and elderly 
people were found in an analysis of SARS-CoV-2 out-
breaks in six care homes in Great Britain. The researchers 
swabbed every resident as well as the staff and followed 
them up for 14 days to classify individuals as being symp-
tomatic, presymptomatic, postsymptomatic or asympto-
matic throughout the study period. Among the elderly 
residents, nearly 40% tested positive, among the younger 
staff approximately 21%. In both groups, the propor-
tion of asymptomatic individuals, was almost 64% at the 
time of testing. Over the course of the study, symptoms 
developed in 31.3% of asymptomatic residents and in 
13.3% of the asymptomatic staff [21]. Extremely low 
asymptomatic carriage was predominantly reported early 
on in the pandemic [2, 22], which might have been due to 
testing being predominantly performed in symptomatic 
individuals.
Our study has some important limitations including 
the retrospective categorization of symptoms related 
to COVID-19 and its reliance on medical chart review. 
However, patients undergo a standardized evaluation 
during admission, improving the quality of such data. 
Furthermore, results are only generalizable to inpatients 
admitted to an acute care facility during a low endemic-
ity setting or to younger patient populations, especially 
children. A higher total number of asymptomatic carriers 
of SARS-CoV-2 may have been identified, when screen-
ing in a higher endemicity setting and including younger 
patient populations.
Conclusion
The high number needed to screen, to identify asympto-
matic SARS-CoV-2 infected patients, questions the bene-
fits of systematic on admission screening. The substantial 
proportion of asymptomatic SARS-CoV-2 infections, 
even in a low prevalence setting, emphasizes the need for 
universal infection and transmission control measures in 
health care institutions to prevent onward transmission 
by undetected SARS-CoV-2-carriers.
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